Xenikos B.V.
Company

Xenikos B.V.

Biotechnology Research Nijmegen, Gelderland, Nl 6 employees
Employees
6

Xenikos B.V. Overview

Headquarters
Nijmegen, Gelderland, Nl
Phone Number
Available in AeroLeads
Website
xenikos.com
Industry
Biotechnology Research
Employees
6
Founded
2009
Funding
2.7M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Xenikos B.V.

Xenikos is a clinical-stage biotechnology company focused on developing a novel therapy that aims to quickly and efficiently reset the immune system of patients suffering from serious immune diseases, or rejection after transplantation. The Company’s lead product candidate, T-Guard®, is currently in Phase 3 development for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD). Based on its mechanism of action, Xenikos believes T-Guard also has the potential to be effective in treating certain other serious immune conditions, such as transplant-related rejection, solid-organ rejection and several severe autoimmune diseases.

Xenikos B.V. Contact Details

Compare Similar Companies to Xenikos B.V.